Dementia, a progressive disorder that impacts memory and independence, affects millions globally. While many are aware of ...

The risk of developing dementia may be double what was previously thought. But there are things the U.S. can do to help fight ...

For many years, platinum-based chemotherapy has been one of the mainstays for advanced testicular cancer. Painful peripheral ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

Study Identifies Potential New Drug for Parkinson's-Related Cognitive Decline, Dementia Nov. 19 ... which could lead to treatments for the cognitive symptoms of Parkinson's ...

Leqembi's subcutaneous dosing allows Alzheimer's patients to administer weekly treatment at home in 15 seconds ... with Mild ...

Nearly 7 million Americans have been diagnosed with dementia, which slowly erodes memory, thinking skills and the ability to ...

Before treatment, patients need a diagnosis confirmed ... based on a blood test as the enrolment criterion for dementia drug trials. That could pave the way for those blood tests, which look ...

SHENZHEN, CHINA, Jan. 08, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce ...

ZUNVEYL will further diversify our Group’s innovative drug product matrix and synergize with ... efficacy and demonstrated long-term clinical benefit in the treatment of mild-to-moderate dementia of ...